Hae Jin Kee Selected Research

2,5-dihydroxybenzoic acid (gentisic acid)

1/2019	Gentisic acid prevents the transition from pressure overload-induced cardiac hypertrophy to heart failure.
12/2018	Gentisic acid attenuates pressure overload-induced cardiac hypertrophy and fibrosis in mice through inhibition of the ERK1/2 pathway.
1/2018	Dendropanax morbifera Prevents Cardiomyocyte Hypertrophy by Inhibiting the Sp1/GATA4 Pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hae Jin Kee Research Topics

Disease

21	Cardiomegaly (Heart Hypertrophy) 01/2022 - 01/2006
15	Hypertension (High Blood Pressure) 01/2022 - 01/2013
13	Hypertrophy 01/2022 - 01/2006
13	Fibrosis (Cirrhosis) 01/2022 - 01/2006
7	Neoplasms (Cancer) 01/2022 - 03/2008
7	Inflammation (Inflammations) 01/2022 - 11/2012
4	Heart Failure 01/2022 - 12/2017
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2017
4	Body Weight (Weight, Body) 01/2021 - 05/2014
4	Hyperplasia 01/2021 - 11/2011
3	Vascular Calcification 11/2017 - 11/2014
3	Brain Ischemia (Cerebral Ischemia) 01/2006 - 09/2002
2	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 11/2017 - 04/2010
2	Thrombosis (Thrombus) 04/2015 - 06/2013
2	Neointima 11/2012 - 05/2012
2	Leukemia 07/2012 - 03/2008
2	Ischemia 07/2004 - 09/2002
1	Atherosclerosis 01/2021
1	Myocardial Infarction 01/2020
1	Ventricular Premature Complexes (Premature Ventricular Contraction) 01/2020
1	Vascular Remodeling 01/2019
1	Essential Hypertension 01/2018
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 12/2017
1	Pulmonary Hypertension 05/2017

Drug/Important Bio-Agent (IBA)

18	Histone Deacetylases (Histone Deacetylase)IBA 01/2022 - 01/2006
13	Histone Deacetylase InhibitorsIBA 01/2022 - 01/2006
10	Angiotensin IIIBA 01/2022 - 01/2006
10	Gallic AcidIBA 01/2022 - 11/2014
9	Isoproterenol (Isoprenaline)FDA LinkGeneric 01/2022 - 11/2008
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2006
6	Transcription Factors (Transcription Factor)IBA 01/2021 - 01/2011
5	EnzymesIBA 01/2022 - 01/2011
4	Valproic Acid (Depakote)FDA LinkGeneric 01/2019 - 01/2006
4	Small Interfering RNA (siRNA)IBA 01/2017 - 05/2011
4	Histones (Histone)IBA 09/2015 - 01/2006
4	trichostatin A (A 300)IBA 11/2011 - 01/2006
3	CollagenIBA 01/2022 - 10/2016
3	Protein Isoforms (Isoforms)IBA 01/2022 - 03/2008
3	PCI 34051IBA 01/2022 - 01/2019
3	sulforaphaneIBA 01/2022 - 11/2012
3	Collagen Type I (Type I Collagen)IBA 01/2021 - 09/2015
3	N-propionylprocainamideIBA 01/2021 - 12/2009
3	2,5-dihydroxybenzoic acid (gentisic acid)IBA 01/2019 - 01/2018
3	Atrial Natriuretic Factor (ANF)IBA 01/2018 - 01/2006
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2006 - 09/2002
2	C.I. direct red 80IBA 01/2022 - 01/2022
2	5-nitro-2-(3-phenylpropylamino)benzoic acidIBA 01/2021 - 01/2021
2	Fibronectins (Fibronectin)IBA 01/2021 - 12/2017
2	p38 Mitogen-Activated Protein KinasesIBA 01/2021 - 01/2016
2	Messenger RNA (mRNA)IBA 01/2021 - 01/2019
2	Acetates (Acetic Acid Esters)FDA Link 01/2019 - 09/2015
2	Desoxycorticosterone Acetate (DOCA)FDA Link 01/2019 - 01/2013
2	Desoxycorticosterone (Deoxycorticosterone)IBA 01/2019 - 09/2015
2	tubastatin AIBA 01/2019 - 09/2015
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2019 - 12/2018
2	Brain Natriuretic Peptide (Natrecor)FDA Link 12/2018 - 01/2018
2	MC1568IBA 05/2018 - 11/2016
2	Connective Tissue Growth FactorIBA 01/2018 - 12/2017
2	AcidsIBA 01/2018 - 12/2017
2	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2018 - 09/2015
2	NG-Nitroarginine Methyl Ester (L-NAME)IBA 05/2017 - 01/2017
2	GoldIBA 01/2017 - 01/2016
2	Histone Deacetylase 2IBA 01/2017 - 11/2008
2	Phosphotransferases (Kinase)IBA 11/2016 - 08/2006
2	3,3',4,5'-tetrahydroxystilbeneIBA 01/2016 - 05/2014
2	ChromatinIBA 09/2015 - 07/2012
2	SaltsIBA 09/2015 - 01/2013
2	MicroRNAs (MicroRNA)IBA 07/2014 - 08/2013
2	theasinensin AIBA 11/2011 - 12/2009
2	Angiogenesis InhibitorsIBA 07/2004 - 09/2002
1	ZincIBA 01/2022
1	Antihypertensive Agents (Antihypertensives)IBA 01/2022
1	CurcuminIBA 01/2022
1	syringic acidIBA 01/2022
1	Therapeutic UsesIBA 01/2022
1	Adrenergic Agonists (Adrenergic Receptor Agonist)IBA 01/2021
1	protocatechuic acidIBA 01/2021
1	Nicotine FDA Link 01/2021
1	Polyvinyl Chloride (PVC)IBA 01/2020
1	salicylhydroxamic acid (SHAM)IBA 01/2020
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2019
1	entinostat (MS 275)IBA 01/2019
1	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2019
1	Hematoxylin (Haematoxylon)IBA 01/2019
1	Bisoprolol (Concor)FDA LinkGeneric 12/2018
1	Mitogen-Activated Protein Kinase 3IBA 12/2018
1	Diltiazem (Cardizem)FDA LinkGeneric 12/2018
1	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 12/2018
1	PhytochemicalsIBA 05/2018
1	Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA 01/2018
1	HesperidinIBA 01/2018
1	Furosemide (Lasix)FDA LinkGeneric 01/2018
1	AntioxidantsIBA 01/2018
1	Nitric Oxide Synthase (NO Synthase)IBA 01/2018
1	Losartan (Cozaar)FDA LinkGeneric 01/2018
1	Carvedilol (Coreg)FDA LinkGeneric 01/2018
1	TeaIBA 12/2017

Therapy/Procedure

2	Stents 04/2015 - 06/2013
1	Denervation 01/2020
1	Therapeutics 05/2018